DRUGS, EXPRESSION VECTORS, AND THEIR APPLICATIONS IN THE TREATMENT OF NAFLD AND RELATED DISEASES
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Mar 6, 2025
app pub date -
Aug 28, 2024
filing date -
Aug 28, 2024
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The application provides drugs, expression vectors, and their applications in the treatment of NAFLD and related diseases, pertaining to the technical field of targeted drugs. The drugs include streptavidin or a recombinant expression vector for streptavidin. Streptavidin can bind to acetyl CoA carboxylase 1, alter its subcellular localization within mammalian cells, and ultimately inhibit de novo lipogenesis. Ectopic expression of streptavidin can inhibit lipid accumulation within mammalian cells. Compared with chemical small-molecule drugs, streptavidin, as a protein drug, exhibits relatively lower liver and kidney toxicity. Streptavidin might be a relatively mild inhibitor of acetyl CoA carboxylase, avoiding a severe side effect of hyperlipidemia. Furthermore, streptavidin is very stable, which might be conducive to drug delivery and adaptable to different administration methods.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully